Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Jul;67(1):7–14. doi: 10.1136/jnnp.67.1.7

Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies

J Antoine 1, J Mosnier 1, L Absi 1, P Convers 1, J Honnorat 1, D Michel 1
PMCID: PMC1736440  PMID: 10369814

Abstract

OBJECTIVE—When to suspect a paraneoplastic disorder is a puzzling problem that has not recently been studied in a large series of patients referred for peripheral neuropathy.
METHODS—From 422 consecutive patients with peripheral neuropathy, 26 were analysed who concomitantly had carcinoma but no tumorous infiltration, drug toxicity, or cachexia. Their clinical, pathological, and electrophysiological data were analysed according to the presence of anti-onconeural antibodies, the latency between presentation and cancer diagnosis, and the incidence of carcinoma in the corresponding types of neuropathy of the population of 422patients.
RESULTS—Seven patients (group I) had anti-onconeural antibodies (six anti-Hu, one anti-CV2) and 19 did not (groups IIA and B). In group I, subacute sensory neuropathy (SSN) was the most frequent but other neuropathies including demyelinating neuropathies were present. Patients in group II A had a short latency (mean 7.88months), and a rapidly and usually severe neuropathy which corresponded in 11/14 to an established inflammatory disorder including neuropathy with encephalomyelitis, mononeuritis multiplex, and acute or chronic inflammatory demyelinating polyneuropathy (CIDP). Patients in group IIB had a long latency (mean 8.4 years) and a very chronic disorder corresponding in four of five to an axonal non-inflammatory polyneuropathy. In this population, the incidence of carcinoma occurring with a short latency was 47% in sensory neuronopathy, 1.7% in Guillain-Barré syndrome, 10% in mononeuritis multiplex and CIDP, and 4.5% in axonal polyneuropathy.
CONCLUSIONS—Paraneoplastic neuropathies associated with carcinoma are heterogeneous disorders. Neuropathies occurring with a long latency with tumours probably resulted from a coincidental association. Neuropathies which occurred within a few years of the tumour evolved rapidly and corresponded mostly to inflammatory disorders. As dysimmune neuropathies are probably paraneoplastic in a limited number of cases, patients with these disorders should probably not be investigated systematically for carcinoma in the absence of anti-onconeural antibodies, except when the neuropathy is associated with encephalomyelitis and probably with vasculitis. Questions remain concerning CIDP.



Full Text

The Full Text of this article is available as a PDF (144.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoine J. C., Honnorat J., Vocanson C., Koenig F., Aguera M., Belin M. F., Michel D. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci. 1993 Jul;117(1-2):215–223. doi: 10.1016/0022-510x(93)90176-y. [DOI] [PubMed] [Google Scholar]
  2. Antoine J. C., Mosnier J. F., Honnorat J., Convers P., Absi L., Lapras J., Michel D. Paraneoplastic demyelinating neuropathy, subacute sensory neuropathy, and anti-Hu antibodies: clinicopathological study of an autopsy case. Muscle Nerve. 1998 Jul;21(7):850–857. doi: 10.1002/(sici)1097-4598(199807)21:7<850::aid-mus2>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  3. Antoine J. C., Mosnier J. F., Lapras J., Convers P., Absi L., Laurent B., Michel D. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):188–190. doi: 10.1136/jnnp.60.2.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barohn R. J., Kissel J. T., Warmolts J. R., Mendell J. R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989 Aug;46(8):878–884. doi: 10.1001/archneur.1989.00520440064022. [DOI] [PubMed] [Google Scholar]
  5. Bird S. J., Brown M. J., Shy M. E., Scherer S. S. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996 Mar;46(3):822–824. doi: 10.1212/wnl.46.3.822. [DOI] [PubMed] [Google Scholar]
  6. Camerlingo M., Nemni R., Ferraro B., Casto L., Partziguian T., Censori B., Mamoli A. Malignancy and sensory neuropathy of unexplained cause: a prospective study of 51 patients. Arch Neurol. 1998 Jul;55(7):981–984. doi: 10.1001/archneur.55.7.981. [DOI] [PubMed] [Google Scholar]
  7. Croft P. B., Urich H., Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain. 1967 Mar;90(1):31–66. doi: 10.1093/brain/90.1.31. [DOI] [PubMed] [Google Scholar]
  8. Dalmau J. O., Posner J. B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 1997 Jun;24(3):318–328. [PubMed] [Google Scholar]
  9. Dalmau J., Graus F., Rosenblum M. K., Posner J. B. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992 Mar;71(2):59–72. doi: 10.1097/00005792-199203000-00001. [DOI] [PubMed] [Google Scholar]
  10. Dropcho E. J. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol. 1996 May;39(5):659–667. doi: 10.1002/ana.410390516. [DOI] [PubMed] [Google Scholar]
  11. Eggers C., Hagel C., Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. J Neurol Sci. 1998 Mar 5;155(2):178–181. doi: 10.1016/s0022-510x(97)00304-3. [DOI] [PubMed] [Google Scholar]
  12. Fagius J. Chronic cryptogenic polyneuropathy. The search for a cause. Acta Neurol Scand. 1983 Mar;67(3):173–180. doi: 10.1111/j.1600-0404.1983.tb04560.x. [DOI] [PubMed] [Google Scholar]
  13. Gorson K. C., Allam G., Ropper A. H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321–328. doi: 10.1212/wnl.48.2.321. [DOI] [PubMed] [Google Scholar]
  14. Graus F., Reñ R. Paraneoplastic neuropathies. Eur Neurol. 1993;33(4):279–286. doi: 10.1159/000116955. [DOI] [PubMed] [Google Scholar]
  15. HENSON R. A., RUSSELL D. S., WILKINSON M. Carcinomatous neuropathy and myopathy a clinical and pathological study. Brain. 1954;77(1):82–121. doi: 10.1093/brain/77.1.82. [DOI] [PubMed] [Google Scholar]
  16. Hallas J., Halls J., Bredkjaer C., Friis M. L. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand. 1988 Aug;78(2):118–122. doi: 10.1111/j.1600-0404.1988.tb03632.x. [DOI] [PubMed] [Google Scholar]
  17. Harati Y., Niakan E. The clinical spectrum of inflammatory-angiopathic neuropathy. J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1313–1316. doi: 10.1136/jnnp.49.11.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Honnorat J., Aguera M., Zalc B., Goujet C., Quach T., Antoine J. C., Belin M. F. POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol. 1998 Apr;57(4):311–322. doi: 10.1097/00005072-199804000-00002. [DOI] [PubMed] [Google Scholar]
  19. Honnorat J., Antoine J. C., Derrington E., Aguera M., Belin M. F. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):270–278. doi: 10.1136/jnnp.61.3.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hormigo A., Dalmau J., Rosenblum M. K., River M. E., Posner J. B. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol. 1994 Dec;36(6):896–902. doi: 10.1002/ana.410360615. [DOI] [PubMed] [Google Scholar]
  21. Lucchinetti C. F., Kimmel D. W., Lennon V. A. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998 Mar;50(3):652–657. doi: 10.1212/wnl.50.3.652. [DOI] [PubMed] [Google Scholar]
  22. McLeod J. G., Tuck R. R., Pollard J. D., Cameron J., Walsh J. C. Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry. 1984 May;47(5):530–535. doi: 10.1136/jnnp.47.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Moll J. W., Antoine J. C., Brashear H. R., Delattre J., Drlicek M., Dropcho E. J., Giometto B., Graus F., Greenlee J., Honnorat J. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology. 1995 Oct;45(10):1937–1941. doi: 10.1212/wnl.45.10.1937. [DOI] [PubMed] [Google Scholar]
  24. Notermans N. C., Wokke J. H., van der Graaf Y., Franssen H., van Dijk G. W., Jennekens F. G. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1525–1527. doi: 10.1136/jnnp.57.12.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. O'Neill J. H., Murray N. M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988 Jun;111(Pt 3):577–596. doi: 10.1093/brain/111.3.577. [DOI] [PubMed] [Google Scholar]
  26. Oh S. J., Dropcho E. J., Claussen G. C. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve. 1997 Dec;20(12):1576–1582. [PubMed] [Google Scholar]
  27. Oh S. J., Slaughter R., Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve. 1991 Feb;14(2):152–156. doi: 10.1002/mus.880140210. [DOI] [PubMed] [Google Scholar]
  28. Peterson K., Forsyth P. A., Posner J. B. Paraneoplastic sensorimotor neuropathy associated with breast cancer. J Neurooncol. 1994;21(2):159–170. doi: 10.1007/BF01052900. [DOI] [PubMed] [Google Scholar]
  29. Peterson K., Rosenblum M. K., Kotanides H., Posner J. B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992 Oct;42(10):1931–1937. doi: 10.1212/wnl.42.10.1931. [DOI] [PubMed] [Google Scholar]
  30. Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl. 1970;44:1–72. doi: 10.1111/j.1600-0404.1970.tb07459.x. [DOI] [PubMed] [Google Scholar]
  31. Uchuya M., Graus F., Vega F., Reñ R., Delattre J. Y. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):388–392. doi: 10.1136/jnnp.60.4.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vincent D., Dubas F., Hauw J. J., Escourolle R., Godeau P., Buge A., Lhermitte F., Castaigne P. Microvasculites nerveuses et musculaires: 50 cas. Rev Neurol (Paris) 1985;141(6-7):440–446. [PubMed] [Google Scholar]
  33. Vincent D., Dubas F., Hauw J. J., Godeau P., Lhermitte F., Buge A., Castaigne P. Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer? J Neurol Neurosurg Psychiatry. 1986 Sep;49(9):1007–1010. doi: 10.1136/jnnp.49.9.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yamada M., Shintani S., Mitani K., Kametani H., Wada Y., Furukawa T., Tsukagoshi H., Ozaki K., Eishi Y., Hatakeyama S. Peripheral neuropathy with predominantly motor manifestations in a patient with carcinoma of the uterus. J Neurol. 1988 Jul;235(6):368–370. doi: 10.1007/BF00314236. [DOI] [PubMed] [Google Scholar]
  35. Younger D. S., Dalmau J., Inghirami G., Sherman W. H., Hays A. P. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology. 1994 Jan;44(1):181–183. doi: 10.1212/wnl.44.1.181-a. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES